Oct 15, 2007 by Brian LawlerPDL BioPharma's Best HopeThe data on daclizumab for multiple sclerosis is encouraging.
Oct 12, 2007 by Brian LawlerOne More Step for MomentaIt continues testing a drug designed to help patients who have suffered heart attacks.
Oct 10, 2007 by Brian LawlerBioenvision Demands a RecountThe drugmaker and Genzyme want to extend voting on their proposed merger.
Oct 9, 2007 by Brian LawlerShire Slims Down, SlightlyThe pharmaceutical sells off some of its marketed drugs.
Oct 8, 2007 by Brian LawlerNoven's Acquisition BluesA recently acquired drug fails a late-stage clinical trial.
Oct 5, 2007 by Brian LawlerOxyContin in the Crosshairs AgainKentucky sues Purdue Frederick, and other drugmakers could benefit.
Oct 4, 2007 by Brian LawlerIs It Time to Sell Your PDL Shares?Following the rise in PDL's price, is it time to let the stock go?
Oct 3, 2007 by Brian LawlerFDA Says Nay to EndoThe FDA rejects Endo's attempts to expand the Frova label.
Sep 28, 2007 by Brian LawlerInterview With PDL Co-Founder Cary QueenInterview with PDL co-founder Cary Queen on the current state of affairs at PDL.
Sep 28, 2007 by Brian LawlerThe Unseen PharmaceuticalsBayer joins the many drugmakers not listed on U.S. exchanges.
Sep 28, 2007 by Brian LawlerBioenvision Shareholder BattleA vote on a proposed acquisition approaches.
Sep 28, 2007 by Brian LawlerInterMune Finds FundingInterMune raises cash via a dilutive stock offering.
Sep 28, 2007 by Brian LawlerGSK Helps Secure Future of a Lead DrugGlaxoSmithKline settles a patent infringement case on a lead drug.
Sep 28, 2007 by Brian LawlerCVT Tries to Supplement ItselfCV Therapeutics applies for a label expansion of Ranexa.
Sep 27, 2007 by Brian LawlerFDA Repeats Itself With Cephalon's FentoraDoctors get a second warning about misusing the pain drug.
Sep 27, 2007 by Brian LawlerViroPharma's Good Bad NewsUnwanted phase 2 results might not scuttle a promising hepatitis C drug.
Sep 27, 2007 by Brian LawlerA Step in a Winding Road for VandaIts latest marketing application includes a new approach to a worrisome treatment.
Sep 26, 2007 by Brian LawlerStop Dragging, PanacosThe company announces another slight delay with its lead drug.
Sep 26, 2007 by Brian LawlerShareholders Pile On Against PDLManagement resignations seen as necessary by those wanting to sell or break apart the biopharma.
Sep 26, 2007 by Brian LawlerPharmasset Shows Off the GoodsThe small-molecule virus-fighter previews its plans.
